Study With Various Immunotherapy Treatments in Participants With Lung Cancer

Recruiting

Phase 2

Study With Various Immunotherapy Treatments in Participants With Lung CancerStudy With Various Immunotherapy Treatments in Participants With Lung Cancer

Sponsor:

Gilead Sciences

Code:

NCT05676931

Conditions

Advanced Non-Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Domvanalimab

Quemliclustat

Zimberelimab

Docetaxel

Platinum-Based Doublet

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-29. This information was provided to ClinicalTrials.gov by Gilead Sciences on 2025-03-25.